GSK plc

GSK

GB00BN7SWP63

Pharmaceuticals

Market Closed - London S.E. Other stock markets 11:35:21 2024-05-10 am EDT			5-day change	1st Jan Change
1,800 ^GBX	+1.07%		+3.81%	+24.09%

May. 08	Gsk plc Announces Board Committee Changes	CI
May. 08	GSK : Receives a Buy rating from Bernstein	ZD

GLAXOSMITHKLINE : UBS remains Neutral

June 24, 2021 at 08:06 am EDT

Laura Sutcliffe from UBS retains his Neutral opinion on the stock. The target price is unchanged and still at GBX 1370.

Latest news about GSK plc

Gsk plc Announces Board Committee Changes	May. 08	CI
GSK : Receives a Buy rating from Bernstein	May. 08	ZD
Bernstein Lifts GSK PT, Keeps Outperform Rating	May. 08	MT
UBS raises Centrica to 'buy' from 'neutral	May. 08	AN
GSK: CITIGROUP RAISES TARGET PRICE TO 2120P FROM 2100P…	May. 08	RE
GSK acquires stake in Swiss BioVersys	May. 07	CF
DZ Bank Keeps GSK at Hold, Raises PT	May. 07	MT
GSK Invests in BioVersys to Speed Development of Potential Tuberculosis Treatment	May. 07	MT
AstraZeneca target raised; Antofagasta lowered	May. 07	AN
BioVersys AG announced that it has received CHF 44.9 million in funding from AMR Action Fund GP, LLC, GSK plc and other investor.	May. 06	CI
GSK : UBS remains its Buy rating	May. 06	ZD
GSK : DZ Bank remains Neutral	May. 03	ZD
GSK plc : Back on track	May. 03
GSK knew about Zantac cancer risk, attorneys tell jury in first trial	May. 02	RE
GSK : Buy rating from Deutsche Bank	May. 02	ZD
GSK : UBS keeps its Buy rating	May. 02	ZD
GSK : UBS reiterates its recommendation on the share	May. 02	CF
Moderna quarterly sales beat expectations but plummet from previous year	May. 02	RE
Deutsche Bank likes TP ICAP but says sell CMC	May. 02	AN
GSK : JP Morgan reaffirms its Sell rating	May. 02	ZD
GSK: JP MORGAN RAISES TARGET PRICE TO 1660P FROM 1530P…	May. 02	RE
Chimeric Therapeutics Appoints COO; Shares Rise 4%	May. 01	MT
Health Care Climbs as Pfizer, GSK Rise -- Health Care Roundup	May. 01	DJ
Top Midday Stories: CVS Reports Q1 Earnings Miss, Lowers Outlook; ADP Q1 Earnings Top Estimates; J&J Proposes $6.5 Billion Settlement for Talc Lawsuits	May. 01	MT
FTSE 100 down ahead of US interest rate decision	May. 01	AN

GSK plc is a global biopharma company. The Companyâs segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. It has developed monoclonal antibodies to help treat different diseases. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes more than 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines include medicines for immune-mediated conditions. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases.

Sector

Pharmaceuticals

Calendar

2024-07-31 - Q2 2024 Earnings Release

Related indices

STOXX EUROPE 600 (EUR) , FTSE 100

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

GSK plc : Back on track

May 03, 2024 at 05:17 am EDT

GSK PLC : Encouraging start to 2024; guidance raised

May 01, 2024 at 11:38 am EDT

More Strategies

Ratings for GSK plc

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

18 GBP

Average target price

20.25 GBP

Spread / Average Target

+12.52%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
GSK PLC	+24.09%	91.83B
ELI LILLY AND COMPANY	+30.38%	684B
NOVO NORDISK A/S	+26.51%	568B
JOHNSON & JOHNSON	-4.36%	361B
MERCK & CO., INC.	+19.30%	329B
ABBVIE INC.	+3.73%	284B
ASTRAZENECA PLC	+16.70%	240B
NOVARTIS AG	+8.78%	208B
ROCHE HOLDING AG	-7.93%	200B
AMGEN INC.	+7.68%	166B

Other Pharmaceuticals

GSK plc

Equities

GSK

GB00BN7SWP63

Pharmaceuticals

GLAXOSMITHKLINE : UBS remains Neutral

Latest news about GSK plc

Chart GSK plc

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for GSK plc

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals